Answers are grounded in this paper and cite their sources.
Deuterium labeling plays a pivotal role in pharmaceutical development by modulating physicochemical properties and enabling metabolic tracing. However, site-selective and programmable deuteration in amine-containing pharmaceuticals remains a formidable challenge, as it typically requires prefunctionalized and costly deuterated reagents that hamper scalability and practical utility. Here, we report an electrochemical strategy for synthesizing deuterated amine pharmaceuticals using D2O as a cost-effective deuterium source, enabling site selectivity, degree-programmable deuteration, and excellent deuterium incorporation. Central to this approach is the electrochemical conversion of toxic polyhalides into reactive deuterated building blocks in situ, facilitating the efficient synthesis of over 70 deuterated drugs, with selective mono-, di-, and trideuteration at the N-benzyl, N-methyl, O-benzyl, and S-benzyl positions, and broad functional-group tolerance. Collectively, we establish a platform integrating polyhalides valorization with precision isotopic editing for accessing high-value deuterated pharmaceuticals, especially amine-containing drugs bearing common metabolic soft spots such as benzyl and methyl motifs.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: